Danaher Corporation acquires Masimo Corporation (2026)

Deal facts

Buyer: Danaher Corporation
Target: Masimo Corporation
Deal value: Not disclosed
Announced: 17 February 2026
Status: Completed
Sector: Healthcare
Country: United States
Consideration: cash

Sources

What we know

Danaher Corporation has agreed to acquire Masimo Corporation in a going private transaction valued at an undisclosed sum. The deal, announced on 17 February 2026, was structured as a cash consideration purchase. Both entities are based in the United States and operate within the healthcare sector. The transaction was completed on 10 June 2026, marking the conclusion of the acquisition process.

The agreement resulted in Masimo Corporation being taken off the public markets under the ownership of Danaher Corporation. No specific financial figures or valuation multiples were reported for this transaction. The completion of the deal signifies the end of Masimo Corporation's status as a publicly listed company. The transaction is now final and has been fully executed by both parties.

More M&A Tools

Explore the Toolkit

Tools, frameworks and AI assistants designed for entrepreneurs serious about M&A.

Access now

Deal timeline

1 update

10 Jun 2026CompletedClosed
Danaher Corporation completes acquisition of Masimo Corporation
INTRODUCTORY NOTE On June 10, 2026 (the “ Closing Date ”), Danaher Corporation, a Delaware corporation (“ Parent ”), completed the previously announced acquisition of Masimo Corporation, a Delaware corporation (the “ Company ”), pursuant to the Agreement and Plan of Merger, dated as of February 16, 2026 (the “ Merger Agreement ”), by and among the Company, Parent, and Mobius Merger Sub, Inc., a De
Source

OpinionExit Mode editorial

We see a definitive shift in the healthcare technology landscape with the completion of Danaher Corporation's acquisition of Masimo Corporation. This transaction, announced on 17 February 2026, moves Masimo from public markets into private ownership through an all-cash deal. The structure is straightforward: a US buyer purchasing a US target to take it private. There is no complex share swap or contingent value right to navigate, which removes a significant layer of uncertainty for the shareholders of Masimo. For the SME founder reading this, the mechanics here are instructive. When a strategic buyer offers a clean cash exit, it signals a desire for full control and the ability to execute a long-term strategy without the quarterly scrutiny of public markets.

The decision to go private often stems from the need to invest heavily in innovation or restructure operations without the immediate pressure of earnings calls. In the healthcare sector, where regulatory hurdles and long product development cycles are the norm, this environment is often preferable to the volatility of a public listing. We note that while the specific value is not disclosed, the all-cash nature of the consideration implies a strong balance sheet from Danaher and a clear valuation agreement between the parties. This contrasts sharply with deals where a portion of the price is held back in escrow or tied to future performance targets. The absence of such contingencies in the announced terms suggests a high degree of confidence in the target's current standing and a willingness to pay a premium for certainty.

This deal reinforces the trend of large industrial and healthcare conglomerates consolidating specialist technology platforms to drive synergies. For founders operating in similar niches, the message is clear. If your business model relies on patient capital and long-horizon R&D, a public listing may no longer be the optimal path. The CMA or other competition regulators may scrutinise such consolidations, but the primary commercial driver here is the strategic fit. The buyer has chosen to absorb the entire risk and reward by paying cash upfront. This is a powerful signal that the buyer sees immediate value in the target's technology and customer base that justifies the full price today.

Your immediate action this week is to review your own capital structure and ask if public market reporting requirements are hindering your ability to execute a five-year plan. If the answer is yes, begin mapping out the specific strategic buyers who would benefit most from your technology and prepare a confidential information memorandum that highlights your long-term value drivers rather than just your last quarter's earnings.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2026 deals More going private deals More from Danaher Corporation All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

6 July 2026CompletedHealthcare

Trafalgar Asset Management, LLC to acquire The Greater Cannabis Company, Inc.

Trafalgar Asset Management, LLC has agreed to acquire The Greater Cannabis Company, Inc. in a going private transaction. The deal was announced on 6 July 2026, following…

Buyer: Trafalgar Asset Management, LLC
Target: The Greater Cannabis Company, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

30 June 2026CompletedHealthcare

Hanmi Pharmaceuticals Co. Ltd. to acquire Aptose Biosciences Inc.

Hanmi Pharmaceuticals Co. Ltd. has agreed to acquire Aptose Biosciences Inc. in a going private transaction valued at USD 3,466,470. The consideration for this deal cons…

Buyer: Hanmi Pharmaceuticals Co. Ltd.
Target: Aptose Biosciences Inc.
Deal value: USD 3,466,470
Deal type: going private

Read deal Healthcare deals going private deals Canada deals

9 June 2026CompletedHealthcare

GlaxoSmithKline LLC to acquire Nuvalent, Inc.

GlaxoSmithKline LLC has agreed to acquire Nuvalent, Inc. in a going private transaction. The deal was announced on 9 June 2026 and completed on 15 July 2026. The conside…

Buyer: GlaxoSmithKline LLC
Target: Nuvalent, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

3 June 2026CompletedHealthcare

FONAR, LLC to acquire FONAR Corporation

FONAR, LLC has agreed to acquire FONAR Corporation in a going private transaction completed on 3 June 2026. The deal involves the purchase of the US-based healthcare com…

Buyer: FONAR, LLC
Target: FONAR Corporation
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

13 May 2026CompletedHealthcare

Zydus Worldwide DMCC to acquire Assertio Holdings, Inc.

Zydus Worldwide DMCC has agreed to acquire Assertio Holdings, Inc. in a going private transaction valued at an undisclosed amount. The deal, announced on 13 May 2026, wa…

Buyer: Zydus Worldwide DMCC
Target: Assertio Holdings, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

Buyer history